Clinical Trial Results:
A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP: OGTT (Oral Glucose Tolerance Test) study to examine the long term effects (3-4 years) of canakinumab in T2DM on endogenous insulin secretion and insulin resistance.
Summary
|
|
EudraCT number |
2012-003011-58 |
Trial protocol |
DE HU IT SK |
Global completion date |
02 Jul 2012
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
29 Nov 2019
|
First version publication date |
29 Nov 2019
|
Other versions |
|
Summary report(s) |
Cancellation letter for CACZ885M2301S2 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.